ADRx Team
James Treanor, Ph.D.
President &
Chief Executive Officer
Mary Auchincloss-Del Bonis
Head of Finance
Marcin Apostol Ph.D.
Director of Molecular Sciences
Ashley Wright Ph.D.
Senior Scientist
Research Team
Founders & Board of Directors
David Eisenberg, Ph.D.
Chairman of Scientific Advisory Board and Co-Founder
John Frank,
Co-Founder, Board Member
James Treanor, Ph.D.
President &
Chief Executive Officer
Gary Wilcox, Ph.D.,
Chairman and Co-Founder
Jim Wells, Ph.D.,
Board Member
Scientific Advisory Board
Kenneth S. Kosik, M.D.,
Dr. Kosik is the Co-Director of the UC Santa Barbara Neuroscience Research Institute and Founder of CFIT, now a program of Santa Barbara Cottage Hospital. He received his M.D. degree from the Medical College of Pennsylvania, and held various appointments at the Harvard Medical School. He is a Neurologist and expert in Alzheimer’s Disease.
https://labs.mcdb.ucsb.edu/kosik/kenneth/
Thomas C. Boone, M.A.,
Tom Boone was formerly Amgen VP, Protein Sciences overseeing a biologics R&D team of over 300 researchers across five sites. Tom currently consults or acts as an advisor for more than 10 companies and owns his own company developing biologics for companion animals.
https://www.linkedin.com/in/tom-boone-98484612
Lyn R. Frumkin, M.D., Ph.D.,
Dr. Frumkin is Consulting Professor at Stanford University School of Medicine and advises industry and venture capital firms on biotech and life sciences investment opportunities. He led clinical drug development programs at Amgen and ICOS Corp. and regulatory strategy for successful approval of pivotal trials.
https://www.linkedin.com/in/lyn-frumkin-md-phd-0239003
William F. DeGrado, Ph.D.,
Dr. Grado is Professor of Pharmaceutical Chemistry at UCSF, after a highly successful careers in drug discovery at Dupont and Dupont Merck.
https://pharm.ucsf.edu/degrado
Nancy Stagliano, Ph.D.,
Dr. Stagliano is an accomplished serial biotechnology entrepreneur serving as chief executive officer three consecutive biotech companies: CytomX Therapeutics (CTMX), iPierian and, most recently, True North Therapeutics.